Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Amryt Pharma
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:CEO |
Marc D. Beer
|
| gptkbp:focusesOn |
rare diseases
|
| gptkbp:foundedIn |
2005
|
| gptkbp:founder |
Marc D. Beer
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aegerion Pharmaceuticals
|
| gptkbp:indication |
gptkb:homozygous_familial_hypercholesterolemia
generalized lipodystrophy |
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
gptkb:Juxtapid
gptkb:Myalept |
| gptkbp:regulates |
gptkb:FDA
gptkb:EMA |
| gptkbp:specializesIn |
lipid disorders
|
| gptkbp:status |
defunct
|
| gptkbp:stockSymbol |
AEGR
|
| gptkbp:bfsParent |
gptkb:Sol_Barer
gptkb:Sol_J._Barer gptkb:lomitapide |
| gptkbp:bfsLayer |
7
|